Cipla Q4 profit drops 55% to Rs 555 crore; board recommends Rs 13 dividend

Pharma major Cipla has reported 55% year-on-year (YoY) fall in its consolidated net profit for the fourth quarter ended March to Rs 555 crore, while total income from operations fell 3% to Rs 6,541 crore.

For the full year FY26, the company reported revenue of Rs 28,163 crore, up 2% YoY, while annual PAT declined 26% to Rs 3,879 crore.

The Board of Directors of the company has recommended a final dividend of Rs 13 per equity share (face value of Rs 2 each) for the financial year ended March.


Commenting on the result, Achin Gupta MD and Global CEO, Cipla, said: “We continue to make considerable progress across our focused markets.…Key therapies in branded prescription business delivered robust double-digit growth, trade generics business sustained the strong growth momentum and anchor brands of consumer health business maintained leadership position.”

“Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front,” he added.

One India business grew at 15% YoY. R&D investments stood at Rs 509 crore or 7.8% of sales for the quarter, driven by product filings and development efforts.

Cipla Q4 profit drops 55% to Rs 555 crore; board recommends Rs 13 dividend.